摘要
目的为临床合理使用注射用重组人白介素-11(rhIL-11)提供参考。方法分析玲珑英诚医院收治的1例使用rhIL-11后出现急性心力衰竭(简称心衰)患者的临床资料,采用诺氏(Naranjo´s)评估量表进行药品不良反应(ADR)关联性评价,结合最新文献分析发病原因,并提出针对性的预防措施。结果此例患者Naranjo´s评估量表评分为6分,评估结果为“很可能有关”。最新研究表明,白细胞介素11可能通过细胞间充质转化程序、旁分泌途径等多种信号通路诱发心衰,可能是一种促炎因子。结论临床医务人员应重视rhIL-11引起的急性心衰,尤其是老年患者。建议用药过程中加强药学监护,以确保患者的用药安全。
Objective To provide a reference for the rational clinical use of Recombinant Human Interleukin-11(rhIL-11)for Injection.Methods The clinical data of a patient with acute heart failure(AHF)treated with rhIL-11 in the Linglongyingcheng Hospital were analyzed.The Naranjo´s Rating Scale was used for correlation evaluation of Adverse Drug Reaction(ADR),the causes of the disease were analyzed in combination with the latest literature,and the targeted preventive measures were put forward.Results The Naranjo´s assessment scale score for this patient was six points,and the assessment result was"likely related".The latest research suggested that interleukin-11 might induce AHF through various signaling pathways such as mesenchymal transition and paracrine pathways,and it might be a pro-inflammatory factor.Conclusion Clinical staff should pay attention to AHF induced by rhIL-11,especially in elderly patients.It is recommended to strengthen pharmaceutical care during the medication,in order to ensure the patients´medication safety.
作者
阎宝清
赵丽娟
邵建州
刘玉鹏
刘川平
孙桐
YAN Baoqing;ZHAO Lijuan;SHAO Jianzhou;LIU Yupeng;LIU Chuanping;SUN Tong(Linglongyingcheng Hospital,Yantai,Shandong 265400,China;The People′s Hospital of Zhaoyuan City,Yantai,Shandong 265400,China)
出处
《中国药业》
2026年第1期134-137,共4页
China Pharmaceuticals
